Biblio

Export 308 results:
[ Author(Desc)] Title Type Year
Filters: First Letter Of Keyword is T  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
M
A. Mahzarnia, Lutz, M. W., and Badea, A., “A Continuous Extension of Gene Set Enrichment Analysis Using the Likelihood Ratio Test Statistics Identifies Vascular Endothelial Growth Factor as a Candidate Pathway for Alzheimer's Disease via ITGA5.”, J Alzheimers Dis, vol. 97, no. 2, pp. 635-648, 2024.
A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
A. Manousopoulou, Saito, S., Yamamoto, Y., Al-Daghri, N. M., Ihara, M., Carare, R. O., and Garbis, S. D., “Hemisphere Asymmetry of Response to Pharmacologic Treatment in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 51, no. 2, pp. 333-8, 2016.
P. R. Manzine, Pelucchi, S., Horst, M. A., Vale, F. A. C., Pavarini, S. C. I., Audano, M., Mitro, N., Di Luca, M., Marcello, E., and Cominetti, M. R., “microRNA 221 Targets ADAM10 mRNA and is Downregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 113-123, 2018.
C. Marr, McDowell, B., Holmes, C., Edwards, C. J., Cardwell, C., McHenry, M., Meenagh, G., Teeling, J. L., and McGuinness, B., “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
C. Marr, McDowell, B., Holmes, C., Edwards, C. J., Cardwell, C., McHenry, M., Meenagh, G., Teeling, J. L., and McGuinness, B., “The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug.”, J Alzheimers Dis, vol. 99, no. 1, pp. 161-175, 2024.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
G. Marwarha, Rostad, S., Lilek, J., Kleinjan, M., Schommer, J., and Ghribi, O., “Palmitate Increases β-site AβPP-Cleavage Enzyme 1 Activity and Amyloid-β Genesis by Evoking Endoplasmic Reticulum Stress and Subsequent C/EBP Homologous Protein Activation.”, J Alzheimers Dis, vol. 57, no. 3, pp. 907-925, 2017.
S. C. McEwen, Siddarth, P., Abedelsater, B., Kim, Y., Mui, W., Wu, P., Emerson, N. D., Lee, J., Greenberg, S., Shelton, T., Kaiser, S., Small, G. W., and Merrill, D. A., “Simultaneous Aerobic Exercise and Memory Training Program in Older Adults with Subjective Memory Impairments.”, J Alzheimers Dis, vol. 62, no. 2, pp. 795-806, 2018.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
E. Morenas-Rodriguez, Cervera-Carles, L., Vilaplana, E., Alcolea, D., Carmona-Iragui, M., Dols-Icardo, O., Ribosa-Nogué, R., Muñoz-Llahuna, L., Sala, I., M Sánchez-Saudinós, B., Blesa, R., Clarimón, J., Fortea, J., and Lleo, A., “Progranulin Protein Levels in Cerebrospinal Fluid in Primary Neurodegenerative Dementias.”, J Alzheimers Dis, vol. 50, no. 2, pp. 539-46, 2016.
J. - P. Morin, Cerón-Solano, G., Velázquez-Campos, G., Pacheco-López, G., Bermúdez-Rattoni, F., and Díaz-Cintra, S., “Spatial Memory Impairment is Associated with Intraneural Amyloid-β Immunoreactivity and Dysfunctional Arc Expression in the Hippocampal-CA3 Region of a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 69-79, 2016.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
J. C. Morris, Roe, C. M., Xiong, C., Fagan, A. M., Goate, A. M., Holtzman, D. M., and Mintun, M. A., “APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging.”, Ann Neurol, vol. 67, no. 1, pp. 122-31, 2010.
D. E. Moss, Perez, R. G., and Kobayashi, H., “Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1285-1294, 2017.
N
M. Nakanishi, Nakashima, T., Shindo, Y., Niimura, J., and Nishida, A., “Japanese Care Location and Medical Procedures for People with Dementia in the Last Month of Life.”, J Alzheimers Dis, vol. 51, no. 3, pp. 747-55, 2016.
M. Nakanishi, Nakashima, T., Shindo, Y., Niimura, J., and Nishida, A., “Japanese Care Location and Medical Procedures for People with Dementia in the Last Month of Life.”, J Alzheimers Dis, vol. 51, no. 3, pp. 747-55, 2016.
D. A. Nation, Ho, J., and Yew, B., “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
D. A. Nation, Ho, J., and Yew, B., “Older Adults Taking AT1-Receptor Blockers Exhibit Reduced Cerebral Amyloid Retention.”, J Alzheimers Dis, vol. 50, no. 3, pp. 779-89, 2016.
E. Niemantsverdriet, Goossens, J., Struyfs, H., Martin, J. - J., Goeman, J., De Deyn, P. Paul, Vanderstichele, H., and Engelborghs, S., “Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 1, pp. 97-106, 2016.
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
O
R. O'Caoimh, Timmons, S., and D Molloy, W., “Screening for Mild Cognitive Impairment: Comparison of "MCI Specific" Screening Instruments.”, J Alzheimers Dis, vol. 51, no. 2, pp. 619-29, 2016.
E. Oldoni, Fumagalli, G. G., Serpente, M., Fenoglio, C., Scarioni, M., Arighi, A., Bruno, G., Talarico, G., Confaloni, A., Piscopo, P., Nacmias, B., Sorbi, S., Rainero, I., Rubino, E., Pinessi, L., Binetti, G., Ghidoni, R., Benussi, L., Grande, G., Arosio, B., Bursey, D., Kauwe, J. S., Cioffi, S. Mg, Arcaro, M., Mari, D., Mariani, C., Scarpini, E., and Galimberti, D., “PRNP P39L Variant is a Rare Cause of Frontotemporal Dementia in Italian Population.”, J Alzheimers Dis, vol. 50, no. 2, pp. 353-7, 2016.

Pages